Comparison

Anti-Human PD-L1 (CD274) (Clone 130021) - 25 µg

Item no. LEIN-B568-25ug
Manufacturer Leinco Technologies
Amount 25 ug
Quantity options 100 ug 25 ug
Category
Type Antibody Monoclonal
Applications FC, IHC
Clone 130021
Specific against Human (Homo sapiens)
Host Mouse
ECLASS 10.1 42030590
ECLASS 11.0 42030590
UNSPSC 12352203
Shipping Condition Room temperature
Available
Manufacturer - Applications
CyTOF®, FC, IHC
Manufacturer - Category
Primary Monoclonal Antibodies>Growth Factors and Cytokines|Primary Monoclonal Antibodies>Immune Checkpoints
Manufacturer - Targets
PD-L1
Country of Origin
USA
Shipping Temperature
Next Day Ambient
Storage Conditions
The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.
Product Description
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
Background
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
Other Applications Reported In Literature
Immunohistochemistry: Suitable for use at concentration of 8-25 µg/mL.
CyTOF-ready:Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
PubMed
PD-L1
Manufacturer - Specificity
Clone 130021 recognizes an epitope on human B7-H1. In direct ELISAs, this antibody shows no cross-reactivity with rhB7-1, rhB7-2, rhB7-H2, rhB7-H3, rmB7-H1 or rmPD-L2.
RRID
AB_2828240
Formulation
This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 6.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Antigen Distribution
PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes.
Immunogen
Purified Recombinant Human CD274/PD-L1 (Accession # Q9NZQ7)
Additional Information
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords
B7-H, B7H1, B7-H1, B7H1PDCD1L1, CD274 antigenMGC142294, CD274 molecule, CD274, PDCD1L1, PDCD1LG1, PDCD1LG1MGC142296, PDL1, PD-L1, PD-L1B7 homolog 1, PDL1PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H, B7-H1, B7H1, human CD274, CD274 antigen, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, human Programmed cell death 1 ligand 1, human programmed death ligand 1, A530045L16Rik, B7h1, Cd274, Pdcd1l1, Pdcd1lg1, human Pdl1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close